Literature DB >> 8399936

Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients.

H M Foy1.   

Abstract

Mycoplasma pneumoniae causes not only pneumonia but also other respiratory syndromes such as bronchitis, bronchiolitis, pharyngitis, and croup. These infections mimic viral respiratory syndromes. Most cases are treated on an outpatient basis. Epidemics take place at intervals of 4-7 years. The incidence rate is highest among school children and second highest among children < 5 years of age. Among persons who have had M. pneumoniae pneumonia, rates of subsequent infection with this organism are low, and immunity appears to increase with age. The carrier state may last for several months. Patients with humoral immunodeficiency often develop severe infections due to M. pneumoniae, with involvement of the joints; in these individuals the carrier state may persist. M. pneumoniae has been isolated from bronchial washings from children with AIDS. These children have recovered from mycoplasmal infection with appropriate antibiotic treatment. Dermatologic, neurological, cardiac, renal, and pulmonary complications occur, although data on their frequency are lacking.

Entities:  

Mesh:

Year:  1993        PMID: 8399936     DOI: 10.1093/clinids/17.supplement_1.s37

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  85 in total

1.  Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults.

Authors:  Robert M Wadowsky; Elias A Castilla; Stella Laus; Anita Kozy; Robert W Atchison; Lawrence A Kingsley; Joel I Ward; David P Greenberg
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

2.  Rationalised prescribing for community acquired pneumonia: a closed loop audit.

Authors:  H Clements; T Stephenson; V Gabriel; T Harrison; M Millar; A Smyth; W Tong; C J Linton
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

Review 3.  Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections.

Authors:  K Loens; D Ursi; H Goossens; M Ieven
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  Detection of Mycoplasma pneumoniae by real-time nucleic acid sequence-based amplification.

Authors:  K Loens; M Ieven; D Ursi; T Beck; M Overdijk; P Sillekens; H Goossens
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

5.  Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".

Authors:  Matthias F C Beersma; Kristien Dirven; Alje P van Dam; Kate E Templeton; Eric C J Claas; Herman Goossens
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

6.  Culture-independent molecular subtyping of Mycoplasma pneumoniae in clinical samples.

Authors:  Roger Dumke; Paul Christian Lück; Christoph Noppen; Christoph Schaefer; Heike von Baum; Reinhard Marre; Enno Jacobs
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

7.  An unrecognized epidemic of Mycoplasma pneumoniae infection in Vienna.

Authors:  Florian Daxboeck; Claudia C Bauer; Ojan Assadian; Gerold Stanek
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 8.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Ιnflammatory or septic arthritis associated with mycoplasma pneumonia in children: Two case reports and review of the literature.

Authors:  Maria Vlachou; Prokopia Dialyna; Christos Bartsocas; Dimitris Dimitriadis
Journal:  Eur J Orthop Surg Traumatol       Date:  2011-10-21

10.  Hyperoside inhibits proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae.

Authors:  Fang Liu; YuHua Zhao; JieMin Lu; ShuangHui Chen; XinGuang Zhang; WenWei Mao
Journal:  Mol Cell Biochem       Date:  2018-10-22       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.